Auxilium Pharmaceuticals Earnings: Here’s Why the Stock is Down Now

Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL) had a loss and missed Wall Street’s expectations, AND came up short on beating the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are down 2.12%.

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Auxilium Pharmaceuticals Inc. Earnings Cheat Sheet

Results: Adjusted Earnings Per Share decreased to $-0.05 in the quarter versus EPS of $-0.04 in the year-earlier quarter.

Revenue: Decreased 10.07% to $66.2 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Auxilium Pharmaceuticals Inc. reported adjusted EPS loss of $0.05 per share. By that measure, the company missed the mean analyst estimate of $0.02. It missed the average revenue estimate of $81.23 million.

Quoting Management: “Auxilium faced some unanticipated challenges with our commercial franchises in the first quarter of 2013 resulting in lower than expected revenues. However, we are excited by the expected revenue growth and operating leverage that our acquisition of Actient will bring to the combined Company moving forward,” said Adrian Adams, Chief Executive Officer and President of Auxilium. “For the remainder of 2013 and beyond, we plan to maintain our focus on strengthening Testim and XIAFLEX commercial execution in addition to seamlessly integrating the Actient employees and products into Auxilium. We will also continue to make measured investments in R&D, while preparing for the potential launch of XIAFLEX for the treatment of Peyronie’s disease, if approved by the FDA, in the fourth quarter of 2013.”

Key Stats (on next page)…